Home › Trial NCT02987400
Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL
- Trial IDNCT02987400
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorArbeitsgemeinschaft medikamentoese Tumortherapie
- Enrollment22
- Start date2017-01-04
- ConditionsLymphoma, Large B-Cell, Diffuse
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.